---
canonical_name: Calcium Alpha-Ketoglutarate
alternate_names: Ca-AKG, CaAKG, Calcium 2-Oxoglutarate, Calcium α-Ketoglutarate, AKG, Alpha-Ketoglutaric Acid, dAKG
canonical_topic: Calcium Alpha-Ketoglutarate for Health & Longevity
short_topic_lc: calcium_alpha_ketoglutarate
creation_date: 2026-0717-0007
creator_ai_fullname: Opus 4.8
---

# Calcium Alpha-Ketoglutarate for Health & Longevity
<section id="top" markdown="1"></section>
Evidence Review created on 07/17/2026 using [AI4L](https://github.com/forever-healthy/AI4L) / Opus 4.8

**Also known as:** Ca-AKG, CaAKG, Calcium 2-Oxoglutarate, Calcium α-Ketoglutarate, AKG, Alpha-Ketoglutaric Acid, dAKG

  
## Motivation
<!-- This motivation section was written last, after the rest of the document was complete, so that it accurately reflects the full scope of the review. -->

Calcium alpha-ketoglutarate (Ca-AKG) is a stabilized, calcium-bound form of alpha-ketoglutarate, a small molecule the body makes naturally as part of the chemical chain that turns food into cellular energy. The same molecule also acts as a helper for enzymes that maintain the chemical "on/off" tags on genes, and its levels in the blood fall steeply with age. That combination has made it one of the most discussed compounds among people trying to slow biological aging.

Interest surged after a laboratory study reported that older mice given the calcium form lived longer and, more strikingly, spent a far smaller share of their lives frail. A small human report later suggested that a branded alpha-ketoglutarate product was linked to lower "biological age" readings, though it lacked a comparison group. Sold cheaply and with a long safety record as a sports supplement, it is now widely available.

This review examines what the evidence does and does not show about Ca-AKG for healthy aging: its proposed mechanisms, the strength of the animal and human data, its likely benefits and risks, sensible dosing, and how it is being tested in ongoing trials.

**[Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol) - [Conclusion](#conclusion)**

  
## Recommended Reading

This section collects high-level, directly relevant expert and academic overviews that introduce alpha-ketoglutarate and its role in aging without duplicating the dedicated database sections below.

<!-- A real-time web search was performed across the prioritized experts (Rhonda Patrick / FoundMyFitness, Peter Attia, Andrew Huberman, Chris Kresser, Life Extension) and the broader longevity literature for content discussing alpha-ketoglutarate by name and in depth. Both general web search and on-site searches were used. -->

* [#357 ‒ A new era of longevity science: models of aging, human trials of rapamycin, biological clocks, promising compounds, and lifestyle interventions – Brian Kennedy, Ph.D.](https://peterattiamd.com/briankennedy/) - Peter Attia

  A long-form podcast in which Peter Attia and aging researcher Brian Kennedy — a co-author of the key mouse and human alpha-ketoglutarate studies — discuss where the compound sits among promising longevity interventions and how it is being tested in humans. It gives realistic, expert framing of the biological-age claims.

* [Alpha-Ketoglutarate dietary supplementation to improve health in humans](https://pubmed.ncbi.nlm.nih.gov/34952764/) - Gyanwali et al., 2022

  A concise narrative review focused specifically on the human evidence, summarizing the older muscle- and wound-healing studies alongside the newer aging data and clearly stating where clinical proof is still missing. It is the best single-source orientation to the human side of the topic.

* [Pleiotropic effects of alpha-ketoglutarate as a potential anti-ageing agent](https://pubmed.ncbi.nlm.nih.gov/33340716/) - Bayliak & Lushchak, 2021

  A mechanistic narrative review that walks through how alpha-ketoglutarate touches energy metabolism, epigenetics, collagen synthesis, and redox balance, and candidly discusses discrepancies between models. Useful for readers who want to understand *why* the molecule might act on aging.

* [Does Rejuvant's Alpha-Ketoglutarate Supplement Reverse Aging via the TruMe (TruAge) Epigenetic Clock?](https://novoslabs.com/does-rejuvants-alpha-ketoglutarate-supplement-really-reverse-aging-according-to-the-trume-truage-epigenetic-clock/) - NOVOS

  A critical appraisal that scrutinizes the widely cited "8-year reversal" report, highlighting the absence of a placebo group and the limits of the clock used. It is a helpful counterweight to marketing claims.

* [Alpha-Ketoglutarate: Benefits and Side Effects](https://www.lifespan.io/topic/alpha-ketoglutarate-benefits-side-effects/) - Steve Hill

  An accessible, balanced primer that covers the history, the proposed benefits, and the safety profile in plain language. It is a good entry point before reading the primary literature.

*Note: Of the prioritized experts, only Peter Attia has a public, directly-relevant deep-dive on alpha-ketoglutarate. Rhonda Patrick's coverage appears only inside her members-only Science Digest with no public article that matches on the intervention; no dedicated alpha-ketoglutarate article was located from Andrew Huberman, Chris Kresser, or Life Extension Magazine despite web and on-site searches. Two academic narrative reviews were therefore included to keep the list at five high-quality, high-level overviews rather than padding with marginal content.*

  
## Grokipedia
<!-- grokipedia.com was searched directly using the browser tool for "alpha-ketoglutarate"; a dedicated primary article titled "Calcium alpha-ketoglutarate" was found and confirmed. -->

* [Calcium alpha-ketoglutarate](https://grokipedia.com/page/Calcium_alpha-ketoglutarate)

  Grokipedia's dedicated page for the intervention, covering its chemistry as the calcium salt of alpha-ketoglutarate, its biological roles, and the preclinical and early human aging research. It provides a broad, referenced encyclopedic overview.

  
## Examine
<!-- examine.com was searched directly using the browser tool; a dedicated supplement page for alpha-ketoglutarate exists and was confirmed. The page is served behind a bot-protection checkpoint, which may intermittently block automated loading. -->

* [Alpha-Ketoglutarate](https://examine.com/supplements/alpha-ketoglutarate/)

  Examine's independent, citation-heavy supplement monograph on alpha-ketoglutarate, summarizing the evidence for its claimed effects and grading the strength of that evidence. It is a rigorous, non-commercial reference for what the human data actually support.

  
## ConsumerLab
<!-- consumerlab.com was searched directly using the browser tool; a dedicated answer/article on AKG for longevity was found and confirmed. -->

* [Does AKG Extend Lifespan and Slow Aging?](https://www.consumerlab.com/answers/does-akg-extend-lifespan-and-slow-aging/akg-dakg/)

  ConsumerLab's consumer-facing analysis distinguishing plain AKG from the more expensive calcium salt and delayed-release forms, and weighing whether the current evidence justifies the cost. It also touches on product quality and value, ConsumerLab's core focus.

  
## Systematic Reviews

No systematic reviews or meta-analyses for Calcium Alpha-Ketoglutarate were found on PubMed as of July 17, 2026.

  
## Mechanism of Action

Alpha-ketoglutarate (AKG) is a central intermediate of the TCA cycle (tricarboxylic acid cycle, the ring of reactions cells use to extract energy from food). Beyond energy production, it is the required co-substrate for a large family of enzymes called 2-oxoglutarate–dependent dioxygenases, which links it directly to several processes central to aging.

* **Epigenetic regulation.** AKG fuels the TET enzymes (ten-eleven translocation enzymes, which strip methyl tags off DNA) and the Jumonji-family histone demethylases (which remove methyl tags from the proteins DNA wraps around). Because these tags are what "epigenetic clocks" read to estimate biological age, AKG availability can, in principle, shift those marks. Its age-related decline is one proposed reason the epigenetic landscape drifts with age.

* **Nutrient-sensing and dietary-restriction mimicry.** In worms and mammalian cells, AKG binds and inhibits ATP synthase (the cell's main energy-generating machine) and thereby suppresses mTOR (mechanistic target of rapamycin, a master growth switch that promotes aging when overactive) while activating AMPK (AMP-activated protein kinase, a low-energy sensor). This pattern mimics calorie restriction and triggers autophagy (the cell's recycling of damaged components).

* **Inflammation.** In aged mice, dietary AKG lowered circulating inflammatory signaling proteins and raised IL-10 (interleukin-10, an anti-inflammatory messenger), a proposed route to reduced frailty.

* **Collagen and connective tissue.** AKG is a co-substrate for the prolyl and lysyl hydroxylases that mature collagen, and it feeds the PHD enzymes (prolyl hydroxylases) that regulate HIF (hypoxia-inducible factor, the low-oxygen response system).

* **Nitrogen handling and antioxidant action.** AKG is a precursor to the amino acids glutamate and glutamine and helps scavenge ammonia; it can also react non-enzymatically with hydrogen peroxide, giving modest direct antioxidant activity.

Competing mechanistic views exist. One camp holds that AKG acts chiefly as a signaling molecule (dietary-restriction mimicry and epigenetic remodeling); another argues that most orally ingested AKG is consumed by gut tissue and rapidly metabolized, so systemic signaling effects in humans may be small — which is precisely why the calcium salt and delayed- or sustained-release formulations were developed.

Key pharmacological properties are only partly characterized. AKG is an endogenous metabolite with a very short plasma half-life (on the order of minutes) because it is quickly drawn into metabolism; it is not selective for a single target, distributes into tissues that take up TCA-cycle substrates, and is metabolized through the mitochondrial TCA cycle rather than by cytochrome P450 enzymes. Human pharmacokinetic data for the calcium salt remain limited.

  
## Historical Context & Evolution

* **Original use.** Alpha-ketoglutarate was first characterized in the 1930s as part of Hans Krebs' description of the citric acid cycle. Practically, salts of AKG (arginine-AKG and ornithine-AKG) were used for decades as sports-nutrition and clinical-nutrition agents — to support muscle protein synthesis, wound healing, and recovery in surgical and critically ill patients.

* **Turn toward aging.** The pivot to longevity came from model-organism work: AKG was shown to extend lifespan in the worm *Caenorhabditis elegans* (2014) by inhibiting ATP synthase and mTOR, and later in flies and yeast. The decisive step for human interest was a 2020 mouse study showing that the calcium salt extended lifespan and sharply reduced late-life frailty. A 2021 retrospective human report — conducted by the companies that sell the product and the biological-age test used (Ponce de Leon Health and TruMe), a direct financial conflict of interest — then linked a branded formulation to lower epigenetic-age readings.

* **Findings, not just reception.** The mouse study reported meaningful lifespan gains alongside a large reduction in the proportion of life spent frail, attributing benefits partly to lower inflammation. The human report described an average reduction of roughly eight years on one methylation clock over about seven months — a striking figure, but from an uncontrolled, retrospective sample.

* **How opinion has shifted.** Enthusiasm has been tempered rather than overturned. The animal data are consistent and mechanistically plausible, but the single human report's lack of a placebo group, small size, and reliance on one clock have kept the field cautious. Newer analyses suggest any human signal may be specific to delayed-release calcium AKG rather than plain AKG, and randomized trials are now underway to settle the question. The current picture is best read as promising-but-unproven, with the evidence still evolving on both sides.

  
## Expected Benefits

<!-- A dedicated search of PubMed, ClinicalTrials.gov, and expert/clinical sources was performed to assemble the full benefit profile before grading. -->

Benefits are graded by the strength of evidence *as it applies to healthy, longevity-oriented adults*. Because no completed randomized trial in humans has yet reported hard outcomes, the ceiling here is deliberately conservative: robust findings exist mainly in animals, so no benefit reaches the High or Medium tier.

### Low 🟩

#### Reduction in Biological (Epigenetic) Age ⚠️ Conflicted

The headline longevity claim. AKG supplies the enzymes that edit DNA methylation, so it is biologically plausible that it could shift an epigenetic clock (a biological-age estimate read from chemical marks on DNA). The human evidence is a single retrospective analysis — conducted by the product's maker and the test provider, a direct financial conflict of interest — of a branded calcium-AKG-plus-vitamins product with no placebo group, and a later large observational analysis found the association held for the delayed-release calcium form but not for plain AKG — leaving open whether the effect is real, formulation-specific, driven by the added vitamins, or an artifact of who chooses to take it. Preclinical support (lifespan and healthspan gains in mice) is stronger than the human data.

**Magnitude:** Uncontrolled human report: ~8-year reduction on one methylation clock over ~7 months; observational estimate ~1.3–1.8 years lower biological age in delayed-release users. Both are unconfirmed by randomized trials.

#### Reduced Systemic Inflammation

Chronic low-grade inflammation ("inflammaging") is a driver of age-related decline, and in aged mice dietary AKG lowered inflammatory signaling proteins while raising the anti-inflammatory messenger interleukin-10. For the proactive adult, this is the most mechanistically coherent benefit, but direct human confirmation is still limited to secondary readouts in early studies.

**Magnitude:** Not quantified in available human studies; in mice, reductions in multiple circulating inflammatory cytokines accompanied reduced frailty.

#### Preservation of Bone Density

In aged rodents, AKG increased bone mass and accelerated bone regeneration by rejuvenating bone-forming stem cells through changes in histone methylation. This is directly relevant to a longevity-minded audience concerned with fracture risk in later decades, though human bone-outcome data are absent.

**Magnitude:** Not quantified in humans; in aged mice, measurable increases in bone volume and improved bone microarchitecture were reported.

#### Reduced Frailty and Improved Healthspan

The most distinctive animal finding is a "compression of morbidity" — mice stayed functionally healthier for a larger share of their lives, not merely living longer. For an audience prioritizing healthy years over maximum years, this is the most appealing signal, but it remains a preclinical result awaiting human functional trials.

**Magnitude:** In mice, median lifespan extension of roughly 10–20% with a substantial reduction in the proportion of life spent frail; no human functional data yet.

### Speculative 🟨

#### Delayed Reproductive (Ovarian) Aging

In mice, long-term AKG preserved egg quantity and quality and supported the systems that maintain chromosome-end integrity, delaying fertility decline. Any relevance to human reproductive aging is entirely extrapolated and unstudied in people.

#### Skin Collagen and Anti-Wrinkle Effects

Because AKG is a co-substrate for collagen-maturing enzymes, it is proposed to support skin structure; a topical AKG cream improved hydration and wrinkles in a small human study. Whether *oral* calcium AKG reaches skin in meaningful amounts is unknown, so this remains mechanistic and anecdotal.

#### Improved Vascular Function and Blood Pressure

Small mechanistic and early clinical work suggests AKG may improve blood-vessel flexibility and endothelial function, and dedicated hypertension and aortic-aneurysm trials are underway. At present there is no controlled human outcome evidence, so the benefit is hypothetical.

#### Muscle Protein Synthesis and Exercise Recovery

Legacy sports-nutrition data (largely from arginine- and ornithine-AKG) suggested support for muscle building and recovery, but results were mixed and often confounded by the co-ingredient. Evidence specific to calcium AKG for this purpose is essentially absent.

  
## Benefit-Modifying Factors

* **Baseline biological age.** The clearest signal to date is that older or biologically-older individuals appear to benefit most; the human report suggested larger apparent effects in those whose biological age exceeded their chronological age, and the main trial deliberately enrolls people who are biologically older than their years.

* **Baseline inflammation and metabolic status.** Because a proposed route of benefit is dampening inflammation and mimicking calorie restriction, those with elevated inflammatory markers or metabolic stress may have more "headroom" to respond than already-optimized individuals.

* **Sex-based differences.** In the pivotal mouse study, lifespan extension was more pronounced in females than males, and the reproductive-aging findings are female-specific; whether any sex difference translates to humans is unknown.

* **Age.** AKG's endogenous levels fall markedly with age, so a repletion rationale is stronger for older adults; younger, healthy adults with abundant endogenous AKG may have less to gain.

* **Pre-existing conditions.** Individuals with well-controlled diet, activity, and low inflammation may see smaller marginal effects, whereas the presence of age-related metabolic decline is the context in which the compound was studied.

  
## Potential Risks & Side Effects

<!-- A dedicated safety search across drug/supplement references (Examine, ConsumerLab, drugs.com-type sources), PubMed, and the trial safety records was performed before grading. -->

Alpha-ketoglutarate has a long human safety record as a nutritional supplement and the calcium salt is generally very well tolerated; reported problems are mostly mild or theoretical. Evidence ceilings are again conservative because long-term, high-quality human safety data specific to longevity dosing are limited.

### Low 🟥

#### Gastrointestinal Discomfort

The most commonly reported real-world effect is mild digestive upset — nausea, loose stools, or stomach discomfort — typically at higher doses or when taken on an empty stomach. It is generally transient and dose-related rather than a signal of harm.

**Magnitude:** Mild and dose-related — more common at higher (multi-gram) doses than at the ~1 g/day typical of aging protocols; usually resolves with dose reduction or taking the supplement with food.

#### Excess Calcium Intake

Each gram of calcium alpha-ketoglutarate carries a meaningful load of elemental calcium, which stacks on top of dietary and other supplemental calcium. For adults already near or above recommended calcium limits, routine dosing could push total intake into a range associated with its own concerns.

**Magnitude:** Roughly 100–150 mg of elemental calcium per gram of Ca-AKG (formulation-dependent); relevant against a ~2,000–2,500 mg/day tolerable upper limit for total calcium.

### Speculative 🟨

#### Kidney Stones and Vascular Calcification

High supplemental calcium from any source has been linked in some studies to kidney stones and, more controversially, to arterial calcification. Whether the modest calcium in typical Ca-AKG dosing contributes meaningfully is unproven, but it is the most plausible long-term concern for the calcium salt specifically.

#### Theoretical Tumor Metabolism in IDH-Mutant Cancers

In cancers carrying a mutation in the IDH enzyme (isocitrate dehydrogenase, a metabolic enzyme), AKG can be diverted into an "oncometabolite" that supports tumor growth. This is a theoretical caution for the small subset of people with such tumors, not a demonstrated risk in healthy users.

#### Unknown Long-Term Effects of Chronic Nutrient-Sensing Suppression

Sustained mimicry of calorie restriction (mTOR suppression, altered epigenetic marks) is presumed beneficial, but the long-term consequences of years of daily supplementation in humans — including any effect on wound healing, growth, or immune surveillance — have not been studied.

  
## Risk-Modifying Factors

* **Genetic and tumor status.** The IDH-mutation caution above is genotype-specific; it is relevant only to individuals with a known IDH-mutant malignancy, not the general user.

* **Baseline calcium and vitamin D status.** Those with high dietary calcium intake, a history of hypercalcemia (elevated blood calcium), or supplementation with high-dose vitamin D are more likely to approach calcium upper limits when adding Ca-AKG.

* **Sex-based differences.** No sex-specific safety signal has been established; calcium-related concerns (stones, bone) differ by sex and age but are not unique to this compound.

* **Pre-existing conditions.** People with kidney stones, chronic kidney disease, primary hyperparathyroidism (overactive parathyroid glands that push up blood calcium), or sarcoidosis (an inflammatory disease that can raise blood calcium) are more sensitive to any added calcium load and face higher risk from the calcium component.

* **Age.** Older adults — the group most likely to use the compound — are also more prone to vascular calcification and impaired calcium handling, so the calcium load warrants more attention with advancing age.

  
## Key Interactions & Contraindications

* **Calcium-binding oral drugs (caution; reduced drug absorption).** The calcium in Ca-AKG can bind and reduce absorption of levothyroxine, tetracycline and fluoroquinolone (e.g., ciprofloxacin, levofloxacin) antibiotics, bisphosphonates (bone-density drugs such as alendronate, risedronate), and oral iron. Mitigating action: separate dosing by at least 4 hours.

* **Thiazide diuretics (caution; hypercalcemia risk).** Thiazides (hydrochlorothiazide, chlorthalidone) reduce urinary calcium excretion; combined with supplemental calcium they can raise blood calcium. Mitigating action: monitor serum calcium if used together.

* **Other calcium and vitamin D supplements (caution; additive calcium load).** Additive with any calcium-containing supplement or antacid and with high-dose vitamin D, which increases calcium absorption. Mitigating action: count Ca-AKG toward total daily calcium.

* **mTOR-inhibiting or dietary-restriction-mimicking interventions (monitor; theoretical additive effect).** Rapamycin, metformin, and aggressive fasting act on overlapping nutrient-sensing pathways; additive effects are plausible but unstudied. Mitigating action: introduce one intervention at a time.

* **Digoxin (monitor; arrhythmia risk with hypercalcemia).** Elevated calcium can potentiate digoxin's cardiac effects. Mitigating action: caution and monitoring in anyone on digoxin.

* **Populations who should avoid or use only under supervision:** people with a known IDH-mutant cancer; those with hypercalcemia, primary hyperparathyroidism, or sarcoidosis; individuals with recurrent calcium kidney stones; those with advanced chronic kidney disease (eGFR <30, meaning kidney filtration below 30% of normal); and pregnant or breastfeeding individuals, for whom no safety data exist.

  
## Risk Mitigation Strategies

* **Count it toward total calcium:** because each gram of Ca-AKG adds roughly 100–150 mg of elemental calcium, tally it with dietary and other supplemental calcium to keep total intake below ~2,000–2,500 mg/day, directly limiting kidney-stone and vascular-calcification risk.

* **Separate from calcium-sensitive medications:** take Ca-AKG at least 4 hours apart from levothyroxine, oral iron, bisphosphonates, and tetracycline/fluoroquinolone antibiotics to prevent the reduced drug absorption that the calcium component can cause.

* **Take with food and start low:** beginning at the lower end of the dose range and taking the supplement with a meal reduces the mild gastrointestinal discomfort that is the most common side effect.

* **Screen calcium-handling before and during use:** check serum calcium (and, if relevant, kidney function) at baseline and periodically, especially in older adults or those on thiazides, to catch hypercalcemia before it causes harm.

* **Avoid in IDH-mutant cancer:** individuals with a known IDH-mutant malignancy should not supplement, mitigating the theoretical risk of feeding the tumor's oncometabolite pathway.

* **Stay within studied doses:** keeping to ~1 g/day of Ca-AKG (or ~2 g of plain AKG), rather than escalating, keeps the calcium load and any nutrient-sensing effects within the range that has been used in reported studies.

  
## Therapeutic Protocol

* **Standard protocol:** the most cited regimen mirrors the human aging report and the ongoing trials — approximately 1 g/day of calcium alpha-ketoglutarate, frequently in a delayed- or sustained-release form, sometimes packaged with low-dose vitamins A and D (as in the branded product studied). Plain AKG protocols typically use higher amounts (~1–3 g/day) to compensate for lower delivery.

* **Competing approaches:** two philosophies coexist without a clear winner. One favors delayed-release calcium AKG at ~1 g/day on the logic that formulation, not raw dose, drives any human effect; the other favors larger doses of inexpensive plain AKG powder. Neither is validated by head-to-head human outcomes.

* **Who popularized each:** the ~1 g delayed-release calcium approach traces to the Ponce de Leon Health / TruMe retrospective report and the National University of Singapore trial program led by Brian Kennedy's group; the higher-dose plain-AKG approach is common in the general longevity-supplement community.

* **Best time of day:** no circadian optimum is established. Because it is proposed to mimic fasting, some practitioners suggest morning or fasted dosing, though taking it with food improves tolerability.

* **Half-life:** free AKG has a very short plasma half-life (minutes), which is the rationale for calcium-salt and sustained-release formulations intended to prolong exposure.

* **Single vs. split dosing:** at ~1 g/day most protocols use a single daily dose; splitting is an option mainly to reduce gastrointestinal discomfort rather than for any proven pharmacological benefit.

* **Genetic considerations:** no validated pharmacogenetic guidance exists; the only genotype-relevant point is avoidance in IDH-mutant cancer rather than dose adjustment.

* **Sex-based differences:** animal data hint at a larger effect in females, but there is no human basis for sex-specific dosing.

* **Age considerations:** older adults are the studied population and the group with the strongest repletion rationale, but also the group in whom the calcium load deserves the most attention.

* **Baseline biomarkers:** a higher baseline biological (epigenetic) age is the characteristic used to select likely responders in the main trial; elevated inflammatory markers may also identify those with more room to benefit.

* **Pre-existing conditions:** calcium-sensitive conditions (stones, hyperparathyroidism, advanced kidney disease) argue for caution or avoidance regardless of the aging rationale.

  
## Discontinuation & Cycling

* **Lifelong vs. short-term:** the compound is positioned as a long-term, ongoing intervention because endogenous AKG stays low with age and any epigenetic effect would presumably require continued use; no defined treatment course exists.

* **Withdrawal effects:** none are known or expected. AKG is an endogenous metabolite, and stopping simply returns intake to dietary baseline.

* **Tapering:** not required; the supplement can be stopped abruptly without a described taper.

* **Cycling:** there is no evidence that cycling maintains or enhances efficacy. Some users cycle informally (e.g., breaks every few months) on general precautionary grounds, but this is not evidence-based.

  
## Sourcing and Quality

* **Form matters most:** the two decisions are salt (calcium AKG vs. arginine- or ornithine-AKG vs. plain AKG) and release profile (immediate vs. delayed/sustained). The human aging data used delayed-release calcium AKG, so buyers seeking to match the studied product should prioritize that combination.

* **Third-party testing:** because AKG is a commodity ingredient sold by many brands, choose products with third-party purity and identity testing (e.g., NSF, USP, or independent certificates of analysis) to confirm dose and screen for contaminants.

* **Reputable sources:** independent testing organizations (such as ConsumerLab) periodically review AKG products; the branded calcium-AKG-plus-vitamins formulation used in the human report and several established longevity-supplement brands that publish testing are reasonable starting points.

* **Label scrutiny:** verify the elemental calcium content per serving, confirm whether vitamins are included, and check that the stated form is genuinely calcium alpha-ketoglutarate rather than a cheaper AKG salt marketed similarly.

  
## Practical Considerations

* **Time to effect:** no meaningful subjective effect should be expected. Any benefit is on biological-aging markers measured over months (the human report averaged ~7 months), not something a user will feel day to day.

* **Common pitfalls:** conflating the cheap plain-AKG powder with the delayed-release calcium form used in studies; ignoring the added calcium load; expecting felt effects; and over-interpreting a single at-home epigenetic-clock reading, which carries substantial measurement noise.

* **Regulatory status:** in the United States it is sold as a dietary supplement, not an approved drug; alpha-ketoglutarate has Generally Recognized as Safe (GRAS, a US Food and Drug Administration food-safety designation) status as a food ingredient. It is not approved to treat, prevent, or reverse aging.

* **Cost and accessibility:** plain AKG is inexpensive and widely available; the delayed-release calcium form and branded formulations cost several times more, which is the main practical trade-off given that these are the versions with human data.

  
## Interaction with Foundational Habits

* **Sleep:** Interaction direction — none established. There is no evidence that AKG improves or disrupts sleep, and no stimulant properties; timing relative to sleep is therefore unconstrained.

* **Nutrition:** Interaction direction — potentiating and practical. As a proposed calorie-restriction mimic, AKG's rationale overlaps with a nutrient-conscious diet; practically, it is best taken with food to limit gastrointestinal upset, and its calcium content should be counted against total dietary calcium. Diets already very high in dairy or calcium supplements reduce the room for added calcium.

* **Exercise:** Interaction direction — potentially complementary, unproven. Exercise itself raises endogenous AKG and activates the same energy-sensing pathways (AMPK), so effects could overlap; legacy sports-nutrition use suggests no interference with training, but there is no evidence it enhances (or blunts) exercise adaptation at longevity doses.

* **Stress management:** Interaction direction — indirect at most. AKG's proposed anti-inflammatory action could theoretically complement stress-reduction practices that also lower inflammation, but no direct effect on cortisol or the stress response has been demonstrated.

  
## Monitoring Protocol & Defining Success

Baseline testing establishes calcium safety and an aging reference point before starting. Because the intended effect is on biological-aging markers rather than symptoms, objective tracking is more informative than how one feels.

Ongoing monitoring cadence: recheck serum calcium and kidney function at about 3 months after starting (sooner if on a thiazide or high calcium intake), then every 6–12 months; reassess an epigenetic clock and inflammatory markers no more often than every 6–12 months, since shorter intervals mostly capture measurement noise.

* Baseline labs and tests: serum calcium, kidney function (eGFR), high-sensitivity inflammation marker, vitamin D, and — for those tracking the primary rationale — an epigenetic-age test.

| Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes |
|-----------|--------------------------|-----------------|----------------|
| Serum calcium | 8.6–10.0 mg/dL (mid-range preferred) | Detects hypercalcemia from the added calcium load | Fasting sample; interpret with albumin or use ionized calcium; check baseline, ~3 months, then 6–12 months |
| eGFR (kidney filtration; estimated glomerular filtration rate) | >90 mL/min/1.73m² | Flags reduced calcium clearance and kidney-stone risk | Conventional cutoff for concern is <60; avoid supplementation if <30 |
| hs-CRP | <1.0 mg/L | Tracks the proposed anti-inflammatory benefit | High-sensitivity C-reactive protein, an inflammation marker; fasting not required; avoid testing during acute illness, which transiently elevates it |
| 25-Hydroxy Vitamin D | 40–60 ng/mL | High vitamin D raises calcium absorption, compounding the calcium load | Conventional "sufficiency" starts at 30 ng/mL; relevant if the product also contains vitamin D |
| Epigenetic age (DNA methylation age) | Biological age at or below chronological age | The primary marker the intervention targets | High test-to-test variability; retest no more than every 6–12 months and use the same provider |

Qualitative markers are of limited value here because no reliable subjective effect is expected, but the following can be tracked informally:

* Energy and perceived recovery from exertion

* General sense of wellbeing

* Absence of new digestive discomfort as a tolerability check

  
## Emerging Research

The near-term evidence picture depends heavily on several randomized trials now running, which should replace the current reliance on a single uncontrolled human report.

* **Alpha-ketoglutarate Supplementation and BiologicaL agE (ABLE):** the pivotal randomized, placebo-controlled trial of 1 g/day sustained-release calcium AKG in 120 middle-aged adults selected for being biologically older than their chronological age, with change in DNA methylation age as the primary endpoint. [NCT05706389](https://clinicaltrials.gov/study/NCT05706389) (Phase 2; National University of Singapore).

* **Calcium alpha-ketoglutarate for human aging:** a randomized study evaluating Ca-AKG over 12 weeks with change in PhenoAge (a blood-based biological-age score) as the primary outcome. [NCT07114536](https://clinicaltrials.gov/study/NCT07114536) (30 participants; Shenzhen Hygieia Biotech).

* **Combination gerotherapeutics for healthspan:** a trial testing AKG alongside other candidate longevity compounds, with cardiorespiratory fitness (maximal oxygen uptake, VO₂ max), cognition, an inflammation index, and lean mass as endpoints. [NCT07475546](https://clinicaltrials.gov/study/NCT07475546) (Phase 3; AgelessRx).

* **AKG and abdominal aortic aneurysm progression:** a trial examining whether AKG slows growth of small aortic aneurysms, testing a vascular application of the compound. [NCT04723888](https://clinicaltrials.gov/study/NCT04723888) (300 participants; RenJi Hospital).

* **AKG for peri-operative geroprotection (AEGIS):** a surgical trial testing whether AKG blunts the inflammatory response to cardiac surgery, a translational test of its anti-inflammatory action. [NCT07031128](https://clinicaltrials.gov/study/NCT07031128) (Phase 4; National University Hospital, Singapore).

* **Future direction — confirming (or refuting) the biological-age signal:** the key open question is whether the striking uncontrolled result reported by [Demidenko et al., 2021](https://pubmed.ncbi.nlm.nih.gov/34847066/) survives a placebo-controlled design; the ABLE protocol was published to test exactly this ([Sandalova et al., 2023](https://pubmed.ncbi.nlm.nih.gov/37217632/)).

* **Future direction — mechanism and formulation in humans:** whether any human benefit is specific to delayed-release calcium AKG (formulation and added vitamins) versus plain AKG remains unresolved, and pharmacokinetic work is needed to establish how much oral AKG reaches the circulation, building on the mouse healthspan findings of [Asadi Shahmirzadi et al., 2020](https://pubmed.ncbi.nlm.nih.gov/32877690/).

  
## Conclusion

Calcium alpha-ketoglutarate is a stabilized form of a molecule the body makes naturally, one that feeds cellular energy production and helps maintain the chemical tags on genes. Both roles decline with age, which is the core reason it has drawn attention as a way to support healthy aging. Its appeal is strengthened by a clean safety record, low cost for the plain form, and easy availability.

The evidence, however, is stronger in animals than in people. In aged mice, the calcium form extended life and, more importantly, reduced the share of life spent frail. In humans, the main support is a single report — produced by the company that sells the product, and without a comparison group — linking a branded product to lower biological-age readings, plus a pattern that may apply only to the delayed-release calcium version. Supporting signals for lower inflammation, better bone maintenance, and vascular effects remain preliminary or confined to laboratory models.

The main practical considerations are modest: mild digestive upset and a calcium load that adds up with other sources. For a proactive adult, the realistic reading is that this is a low-risk, inexpensive, and biologically plausible option whose central promise is genuinely unproven, with several randomized trials now underway that should soon clarify whether the early enthusiasm holds.

**[Top](#top) - [Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol)**